|
















| |
Schizophrenia Update

Schizophrenia.com Update
I apologize for the delay in getting this out - work and other activities
have limited the time I can devote to
www.schizophrenia.com. In fact, its
becoming obvious that we need someone who can devote more time to the site
if it is to reach its potential. So, I'm now officially looking for a new
Executive Director (volunteer) for the
schizophrenia.com non-profit
organization. So far I've already had one person express interest - which is
a good start - and I'm looking for more potential candidates, especially
people who have some business management and/or non-profit organization
management experience who can really drive things forward. Fund raising
experience would be a definite plus. Top on our list of priorities will be
finding additional funding sources - and to organize a User Committee to
help guide in the development of the web site and in setting priorities.
If you, or someone you know, might be a good candidate for this position
(Schizophrenia.com Executive Director) - please have them contact me at
szwebmaster@yahoo.com)
Schizophrenia and Insulin? One other request... A researcher has
asked me if I've if I've heard if anyone has anyone noticed beneficial or
negative effects on their schizophrenic symptoms post insulin treatment. If
you know of anyone (or a clinician who has treated someone in this
situation) who has had both schizophrenia and diabetes - and been treated
with insulin - and the insulin has seem to have had either negative or
positive effects on the schizophrenic symptoms - please drop me an email and
let me know.
Thanks,
Brian (szwebmaster@yahoo.com)

Table of Contents

Merck Research Chief Plans to Step Down to Pursue Treatments for Mental
Illness
Edward Scolnick to Return to Labs, Seek Methods to Treat Mental Illness
By GEETA ANAND, THE WALL STREET JOURNAL
Merck & Co. said its head of drug research, Edward Scolnick, was stepping
down after 17 years and plans to go back into the laboratories as a
scientist pursuing treatments for mental illness, a personal crusade
motivated by a family history of psychiatric disease.

December 11, 2002
Brain Imaging May Detect Schizophrenia in Early Stages
By ERICA GOODE, New York Times
Scientists have known for some time that people who suffer from
schizophrenia show abnormalities in the structure of their brains.
But
in a new study, researchers for the first time have detected similar
abnormalities in brain scans of people who were considered at high risk for
schizophrenia or other psychotic illnesses but who did not yet have
full-blown symptoms. Those abnormalities, the study found, became even more
marked once the illness was diagnosed.
The
subjects in the study who went on to develop psychoses had less gray matter
in brain areas involved in attention and higher mental processes like
planning, emotion and memory, the researchers found.
Experts said the study's results, reported yesterday in an online version of
The Lancet, the medical journal, offered the possibility that imaging
techniques might eventually be used to predict who will develop
schizophrenia, a devastating illness that affects more than 2.8 million
Americans. Doctors could then offer treatment while the disease was still in
its earliest stages, possibly preventing further damage to the brain.
But
Dr. Christos Pantelis, an associate professor of psychiatry at the
University of Melbourne and the lead author of the report, cautioned that
much more research was needed before magnetic resonance imaging, the method
used in the study, could serve as a diagnostic tool for individual people
with schizophrenia.
"I
think it's still too early to say how helpful it will be," Dr. Pantelis
said.
Still, other researchers called the study's findings exciting and said that
the areas of the brain in which the abnormalities were found would now be an
active focus for study.
"This is a terrific first step," said Dr. Paul Thompson, a professor of
neurology at the University of California at Los Angeles and an expert on
brain imaging and schizophrenia.
Dr.
Herbert Y. Meltzer, a professor of psychiatry at Vanderbilt University and
an expert on schizophrenia, said, "It proves that the psychosis is almost a
late stage in the evolution of the disease process."
He
added, "The key message is that this is a neurodevelopmental disorder and
that changes in memory, learning, attention and executive decision-making
precede the experience of the psychosis."
People who suffer from schizophrenia typically experience auditory
hallucinations and have blunted emotional responses and difficulty with
activities that require planning or other higher-level processes.
Some studies have suggested that the earlier the illness is treated with
antipsychotic drugs the better the prognosis. At least two research groups,
one led by Dr. Patrick McGorry, an author of the Lancet report, and another
at Yale, are conducting studies in which young people who are experiencing
some symptoms but have not yet developed schizophrenia are treated with
antipsychotic drugs. But the studies have been controversial because it is
not yet clear which symptoms predict later illness.
In
the new study, the researchers used magnetic resonance imaging to scan the
brains of 75 people who were deemed "at high risk" for psychosis because
they had a strong family history of severe mental illness or had other risk
factors, including transient or mild symptoms of mental disturbance or a
decline in mental functioning.
Over the next 12 months, 23 of the subjects developed a full-blown psychosis
and 52 did not fall ill, the researchers found.
A
comparison of the brain scans from the two groups revealed significant
differences in the volume of gray matter in areas of the frontal and
temporal lobes and the cingulate gyrus. All three regions have been linked
to schizophrenia by previous research, Dr. Pantelis said.
When the researchers conducted additional brain scans on some subjects who
developed psychoses, they found further reductions in gray matter not seen
in the scans taken before the illnesses were diagnosed.
===========================
From the University of California at Los Angeles:
10 Keys to Recovery From Schizophrenia
UCLA Neuropsychiatric Institute researchers have identified 10 key factors
to recovery from schizophrenia. The findings open opportunities to develop
new treatment and rehabilitation programs and to reshape the negative
expectations of many doctors, patients and their families.
Based on analyses of the professional literature and the cases of 23
schizophrenia patients who successfully returned to work or school with
their symptoms under control, the findings appear in the November 2002
edition of the International Review of Psychiatry.
Factors detailed in the study that influenced recovery included 1) family
relationships, 2) substance abuse, 3) duration of untreated psychosis, 4)
initial response to medication, 5) adherence to treatment, 6) supportive
therapeutic relationships, 7) cognitive abilities, 8) social skills, 9)
personal history and 10) access to care.
"Our findings join a growing body of research that flies in the face of the
long-held notion that individuals diagnosed with schizophrenia are doomed to
a life of disability with little expectation for productive involvement in
society, a fatalistic view that in itself is damaging to prospects for
recovery," said lead author Dr. Robert P. Liberman, a research scientist at
the UCLA Neuropsychiatric Institute and professor of psychiatry at the David
Geffen School of Medicine at UCLA.
"By
understanding the dynamics of recovery, we can design more effective courses
of treatment and combat the pessimism held by many doctors, patients and
families struggling to cope with this debilitating disease," said Liberman,
director of the UCLA Psychiatric Rehabilitation Program and Center for
Research on Treatment and Rehabilitation of Psychosis. "Increasing the rate
of recovery from schizophrenia will help destigmatize this disease, reduce
the emotional burden on families, and lighten the financial weight on
communities, states and the nation."
Liberman and his collaborator, Dr. Alex Kopelowicz, medical director of the
San Fernando Mental Health Center and associate professor of psychiatry at
UCLA, edited the November 2002 edition of the International Review of
Psychiatry. Their articles are joined by those from an international array
of investigators on the process of recovery, prospects for improving
schizophrenia treatment and suggestions for future research.
Factors identified as keys to recovery from schizophrenia included:
1.
Family relationships: Family stress is a powerful predictor of relapse,
while family education and emotional support decrease the rate of relapse.
Among study participants, 70 percent reported good or very good family
relationships.
2.
Substance abuse: National Institute of Mental Health research estimates the
prevalence of lifetime substance abuse among schizophrenia patients at 47
percent, well above the overall rate. Though three-quarters of the study
participants reported substance abuse prior to treatment, just 17.4 percent
reported abuse after the onset of schizophrenia. None reported illicit drug
use in the past year, and just two reported occasional alcohol consumption.
3.
Duration of untreated psychosis: Longer duration of symptoms prior to
treatment correlates directly with greater time to remission and a lesser
degree of remission. Among study participants, only 13 percent reported a
delay of more than a year between the onset of symptoms and treatment.
4.
Initial response to medication: Improvement of symptoms within days of
receiving antipsychotic drugs significantly predicts long-term results of
treatment. Among the study group, 87 percent reported effective control of
symptoms with their first antipsychotic medication.
5.
Adherence to treatment: Failure to take antipsychotic medication as
prescribed hampers both short-term and long-term recovery. All study
participants reported adherence to psychiatric care and medication regimens.
6.
Supportive therapy: Positive relationships with psychiatrists, therapists
and/or treatment teams engender hope and are essential to improvement. Among
study participants, 91 percent reported ongoing psychotherapy, and 78
percent reported that accessible and supportive psychiatrists and therapists
contributed to their recovery.
7.
Cognitive abilities: Neurocognitive factors such as working memory,
sustained attention and efficient visual perception are strong predictors of
recovery. Among study participants, all showed normal or near normal
functioning on tests of flexibility in solving problems, verbal working
memory and perceptual skills.
8.
Social skills Negative symptoms, or poor interpersonal skills relative to
social expectations, correlate with the degree of disability caused by
schizophrenia. No study participants showed more than very mild negative
symptoms.
9.
Personal history: Premorbid factors, or those in place prior to the onset of
the disease, that affect treatment outcome include education and IQ, age of
onset, rapidity of onset, work history, and social skills. Among study
participants, level of education was used as a measure of premorbid history.
A total of 70 percent graduated from college before becoming ill, and an
additional 13 percent completed two years of college. Three of the remaining
four subjects worked full time before their illness began.
10.
Access to care: Continuous, comprehensive, consumer-oriented and coordinated
treatment is crucial to recovery. Among study participants, 91 percent
reported receiving antipsychotic medication and psychotherapy, 47.8 percent
social skills training, 56.5 percent family participation, 26 percent
vocational rehabilitation, and 61 percent benefits from self-help groups.
The
study:
Schizophrenia encompasses a group of psychotic disorders characterized by
disturbances in thought, perception, emotion, behavior and communication
that last longer than six months. In addition, the disorders are associated
with disability in work, school, social relations and independent living
skills. The cause or causes of schizophrenia is unknown. Genetic factors may
play a role, as identical twins and other close relatives of a person with
schizophrenia are more likely to develop the disorder. Psychological and
social factors, such as drug abuse, stressful life challenges and
interpersonal relationships, may also play a role in development.
In
identifying factors to recovery, Liberman and his team reviewed a growing
body of literature that show recovery from schizophrenia can occur under two
conditions: 1) when the disorder is treated early with assertive case
management and use of antipsychotic medication; and 2) when more chronic or
relapsing forms are treated for lengthy periods of time with comprehensive,
continuous care.
In
addition, the researchers examined the cases of 23 schizophrenia patients
who met specific recovery criteria, including remission of symptoms as well
as successful functioning at work and school, independent living and social
relationships.
The
National Institute of Mental Health and the National Alliance for Research
on Depression and Schizophrenia funded the study. UCLA Neuropsychiatric
Institute researchers involved in the study with Liberman included
Kopelowicz, Dr. Joseph Ventura and Dr. Daniel Gutkind.
The
UCLA Neuropsychiatric Institute is an interdisciplinary research and
education institute devoted to the understanding of complex human behavior,
including the genetic, biological, behavioral and sociocultural
underpinnings of normal behavior, and the causes and consequences of
neuropsychiatric disorders. In addition to conducting fundamental research,
the institute faculty seeks to develop effective treatments for neurological
and psychiatric disorders, improve access to mental health services, and
shape national health policy regarding neuropsychiatric disorders.

(relatively) New Books on Schizophrenia:
October 4, 2002
No
Sign Yet Of That Smoking Gun - Book Reviews By: Daniel Nettle
Note: Links below take you to the Amazon.com link for purchasing the book.
The Amazon link also has 25 pages of sample reading from Nancy Andreasen's
book for your review.
Brave New Brain: Conquering Mental Illness in the Era of the Genome
By Nancy C. Andreasen Oxford University Press 368pp, Pounds 24.99 ISBN 0 19
514509 7
In
Search of Madness: Schizophrenia and Neuroscience By R. Walter
Heinrichs Oxford University Press 347pp, Pounds 32.50 ISBN 0 19 512219 4
Hardly a week goes by without our reading of a particular psychological
disorder that has been traced to a rogue brain chemical, or brain area, or
beyond that to a genetic variant. These two books, in their different ways,
reflect the fact that psychiatric research today sits at the intersection of
neuroscience and genetics, and a very long way from the psychodynamic
terrain it once occupied. Nancy Andreasen is one of the ushers of this
ongoing paradigm shift. Twenty years ago, one of her books, The Broken
Brain, became the general reader's herald that the scientific consensus
about psychological disorders was shifting. Here she returns to survey the
ground, choosing this time the new genetics and brain scanning as the tools
that are making light the dark recesses of the mind. Andreasen's book is a
solid enough overview of some aspects of modern biological psychiatry. Her
summaries of the techniques of contemporary human genetics, and of brain
scanning and the cerebral architecture it reveals, are extremely clear and
useful. By the time she comes to survey the main psychological disorders,
though, she has run out of steam slightly. Thus, while these chapters
constitute useful introductions to schizophrenia, affective disorders,
anxiety and dementia for those who have no prior knowledge, there is little
in the way of synthesis of what we now understand to be the nature of these
disorders or of the puzzles that remain.
In
the case of schizophrenia, for example, far from the twin searchlights of
genetics and brain-scanning locating a nice clean smoking gun, they have
revealed much more complexity and variability than we could possibly have
imagined. Despite some welcome words about the need to avoid obstructive
dichotomies (nature vs nurture, brain vs mind), Andreasen is not prepared to
engage with the possibility that neurobiological research might make us
question the whole conceptual framework - a set of neat, discontinuous
disease categories - that her book employs. Anxiety and mood disorders, for
example, are treated as separate chapters in the book without comment, while
genetic and neurobiological evidence leads us increasingly to think of them
as related or even different aspects of the same thing. Many of the brain
abnormalities (and some of the genetic loci) associated with schizophrenia
are also associated with bipolar mood disorders, a crossover difficult to
accommodate within a discrete framework.
R.
Walter Heinrichs's book takes us on a journey through the scientific
literature on schizophrenia in search of the pathognomon. The fascinating
thing about schizophrenia is not, as is sometimes alleged, that no physical
basis has been found to the illness. On the contrary, physical differences
between patient and control brains have been found in terms of overall size,
size of various sub-parts, gray-matter thickness, neuronal density, neuronal
orientation, size of cerebral ventricles, dopamine activity levels, density
of D2 and D4 dopamine receptors, serotonin activity, glutamate... The list
is almost endless. The problem is knowing which of these manifold
differences is significant, especially since many of them have not proved
consistent.
Heinrichs's methodology is so simple as to be beautiful, and produces
wonderful clarity in a confusing field. He meta-analyses the literature on
each of the pathognomic contenders. This is no mean feat since 2,000
research papers are published on schizophrenia each year. He concentrates
not just on the statistical significance of differences, but on effect size,
that is the magnitude of difference between patients and controls. For each
abnormality, he comes up with a mean-effect size from the literature - a
kind of balance sheet of the research world's findings.
The
results are most illuminating. First, despite a lot of variability and
non-replication, the balance of evidence shows that the brains (and
behaviours) of schizophrenia sufferers do differ significantly from those of
the rest of the population in multiple ways. Second, there is no single
trait that is much more pathognomic than any other - no smoking gun. Third,
the degree of difference is in no case very great. On many measures,
schizophrenic brains differ from the rest of the population by about one
standard deviation. This means that they are measurably different, but there
is a range of variation in both patients and controls, and there is huge
overlap between those who receive the diagnosis of schizophrenia and those
who do not. Thus we have a huge amount of physical information that is all
relatively poor at identifying the individuals with the disorder.
These are important results to have. The physical basis of schizophrenia is
an area dogged by researchers narrowly pursuing their own favoured
abnormality, be it dopamine receptors, glutamate or neuronal migration,
without reference to other paradigms that are out there, and without an
attempt to achieve an overall synthesis. The frequency of non-replication
makes it difficult to know which results to rely on, and Heinrichs's method
solves that problem. The work is pursued with great clarity and
thoroughness. The only omission I noted was the failure to cover differences
of asymmetry and lateralisation in the schizophrenic brain.
In
short, the new techniques of genetics, brain-scanning and the like mean that
we have no shortage of information about the basis of psychological
disorders. Heinrichs in particular has given us a magisterial assessment of
some of that evidence. The goal now must be to synthesise it into a more
satisfactory conceptual framework.
Daniel Nettle is lecturer in biological psychology, Open University.

National Post (f/k/a The Financial Post)
October 3, 2002 Thursday National Edition
Mental, neurological ills to draw US$5B Pfizer spending
GROTON, Conn. - Pfizer Inc. plans to spend about US$5-billion during the next
five years to develop new treatments for neurological disorders and mental
illness. A Pfizer spokesman said the pharmaceutical giant invested about
US$1-billion, out of a total US$5.3-billion research and development budget,
into these disorders in 2002. The company expects this commitment to continue
for the next five years, making up the US$5-billion total. Pfizer's
Neuroscience Research and Development Program is developing treatments for
disorders such as depression and anxiety, epilepsy, Alzheimer's disease,
schizophrenia, neuropathic pain and migraine.

Is
paternal age linked to schizophrenia risk in offspring?
Men who
have a child in their advancing years may convey an increased risk of
schizophrenia to their child, reveals a team from the US.
Even
after accounting for maternal age and other confounding factors, the
researchers found that for every 10-year increase in the age of the father at
the birth of their child, the risk of that baby developing schizophrenia in
adulthood increased by almost 1.5 times.
Alan
Brown (New York State Psychiatric Institute, New York) and colleagues used
data from the birth cohort of the Prenatal Determinants of Schizophrenia study
to determine the relation of paternal age to schizophrenia or other
schizophrenia spectrum disorders in 71 patients.
Analysis
of paternal age as both a continuous and categorical variable revealed a
monotonic increase in the rate of schizophrenia spectrum disorders with
advancing paternal age categories.
Indeed,
there was almost twice the rate of adult schizophrenia spectrum disorders in
children of men who were 10 years older at the child's birth, irrespective of
adjustment for maternal age, paternal education, paternal race/ethnicity, and
parity.
When the
risk of schizophrenia alone was assessed, paternal age showed a similar
dose-related increase for risk as that found for schizophrenia spectrum
disorders.
Discussing potential explanations for their findings in the American Journal
of Psychiatry, the authors suggest a possible role of de novo mutations. These
mutations, which accumulate with advancing paternal age, result from
replication errors and defective DNA repair mechanisms that are thought to
propagate in successive clones of spermatocytes.
"While
further work is necessary to confirm this interpretation, our study
nonetheless provides further evidence that advanced paternal age is a risk
factor for schizophrenia spectrum disorders," the researchers report.
Am J
Psychiatry 2002; 159: 1528–1533

Cannabis link to mental illness strengthened
BBC News
23:01 21 November 02
Emma Young
The link between regular cannabis/marajuana use and later depression and
schizophrenia has been significantly strengthened by three new studies.
The
studies provide "little support" for an alternative explanation - that people
with mental illnesses self-medicate with marijuana - according to Joseph Rey
and Christopher Tennant of the University of Sydney, who have written an
editorial on the papers in the British Medical Journal.
One
of the key conclusions of the research is that people who start smoking
cannabis as adolescents are at the greatest risk of later developing mental
health problems. Another team calculates that eliminating cannabis use in the
UK population could reduce cases of schizophrenia by 13 per cent.
Until
now, say Rey and Tennant, there was "a dearth of reliable evidence" to support
the idea that cannabis use could cause schizophrenia or depression. That lack
of good evidence "has handicapped the development of rational public health
policies," according to one of the research groups, led by George Patton at
the Murdoch Children's Research Institute in Melbourne, Australia.
The
works also highlights potential risks associated with using cannabis as a
medicine to ease the symptoms of muscular sclerosis, for example.
Pharmacological effect
Patton's team followed over 1600 Australian school pupils aged 14 to 15 for
seven years. Daily cannabis use was associated with a five-fold increased risk
of depression at the age of 20. Weekly use was linked to a two-fold increase.
The regular users were no more likely to have suffered from depression or
anxiety at the start of the study.
The
reason for the link is unclear. Social consequences of frequent cannabis use
include educational failure and unemployment, which could increase the risk of
depression. "However, because the risk seems confined largely to daily users,
the question about a direct pharmacological effect remains," says Patton.
In
separate research, a team led by Stanley Zammit at the University of Cardiff,
UK, evaluated data on over 50,000 men who had been Swedish military conscripts
in 1969 and1970. This group represents 97 per cent of men aged 18 to 20 in the
population at that time.
The
new analysis revealed a dose-dependant relationship between the frequency of
cannabis use and schizophrenia. This held true in men with no psychotic
symptoms before they started using cannabis, suggesting they were not
self-medicating.
Genetic factors
Finally, researchers led by Terrie Moffitt at King's College London, UK,
analysed comprehensive data on over 1000 people born in Dunedin, New Zealand
in 1972 and 1973.
They
found that people who used cannabis by age 15 were four times as likely to
have a diagnosis of schizophreniform disorder (a milder version of
schizophrenia) at age 26 than non-users.
But
when the number of psychotic symptoms at age 11 was controlled for, this
increased risk dropped to become non-significant. This suggests that people
already at greater risk of later developing mental health problems are also
more likely to smoke cannabis.
The
total number of high quality studies on cannabis use and mental health
disorders remains small, stress Rey and Tennant. And it is still not clear
whether cannabis can cause these conditions in people not predisposed by
genetic factors, for example, to develop them.
"The
overall weight of evidence is that occasional use of cannabis has few harmful
effects overall," Zammit's team writes. "Nevertheless, our results indicate a
potentially serious risk to the mental health of people who use cannabis. Such
risks need to be considered in the current move to liberalise and possibly
legalise the use of cannabis in the UK and other countries."
Journal references: British Medical Journal (vol 325, p1195, p1199, p1212,
p1183)

Australia Scientists Identify Schizophrenia Genes
Tue Nov 26, 1:29 PM ET Add Health - Reuters to My Yahoo!
MELBOURNE (Reuters) - An Australian research team said on Tuesday it had
identified 153 genes affected by schizophrenia in a step toward discovering
the causes of the illness.
The
153 affected genes were identified after completing high-throughput screening
of 12,000 genes in post-mortem studies of brain tissue from schizophrenia
sufferers.
"Within that affected group will be the core genes that actually cause the
symptoms of the illness, and clearly that is what we are trying to get at,"
Mental Health Research Institute Associate Professor Brian Dean told Reuters.
The
research team at the institute's Rebecca Cooper Laboratories outlined its
plans to identify the core genes to the Australian Health and Medical Research
Congress.
"I
think what is important about this is up until now schizophrenia is a
psychiatric illness that is defined on symptoms alone," Dean said.
"What
this gene screen has allowed us to do with our research into the future, is
now base our research on genes that we now know are affected in brain tissue
from someone with the illness."
Dean
said general current thinking is that genetics plays a major role in the
development of schizophrenia, but studies with the identical twins of
sufferers suggest there must also be another factor that brings on the
disease.
"They
have got identical genetic material essentially, but the likelihood of them
getting the illness is only actually 46%," he said.
"There has to be something else other than genes involved, but if we can get
at the core genes, then we can start thinking about what the second hit might
be that affects the susceptible individual."
The
research has implications for improving treatment of the disease without some
of the side effects of existing medication. The next stage involves more
advanced screening of protein and genetic material, known as mRNA, to try and
narrow down the number of genes that actually cause schizophrenia to possibly
five or 10.
"The
core of the problem rests in those genes," Dean said.

Israeli Biotech: Schizophrenia Associated With the COMT Gene
IDgene Pharmaceuticals (Jerusalem) says it has discovered an association
between the COMT (catechol-O-methyltransferase) gene and schizophrenia. The
details of this finding will be published in next month's issue of The
American Journal of Human Genetics and are now available online at
www.journals.uchicago.edu/AJHG/home.html. "The genetic basis of
schizophrenia is poorly understood and the data presented to date has been
mostly inconclusive. IDgene has successfully produced the most statistically
significant results ever reported in schizophrenia or in any other common
polygenic disease. The study shows that the COMT gene may account for more
than 20% of all schizophrenia patients. In the near future, we expect several
additional discoveries of novel disease susceptibility genes, as well as genes
responsible for variation in drug response," notes IDgene's CEO, Ariel Darvasi.

University Of Toronto , 11/13/2002
Gene Increases Schizophrenia Risk, Says Study
Scientists at U of T have discovered the first "risk gene" for schizophrenia
found in the general population.
An
uncommon variation of a gene called Nogo, when inherited from both parents,
increases the risk of developing schizophrenia, says a study to be published
in Molecular Brain Research Nov. 15. Previous findings about other risk genes
for the disease were restricted to specific ethnic groups.
"Finding a risk gene in the general population - the first finding of this
type internationally - opens the door to discovering new and related risk
genes. Now scientists will know where to look for related genes," says
pharmacology and psychiatry professor Philip Seeman. "This will help in
diagnosis and potentially in the design of new medications for treatment of
this terrible disease," adds Seeman who worked on the study with psychiatry
professor Teresa Tallerico, lead author and pharmacology graduate student
Gabriela Novak and undergraduate student David Kim.
The
study shows that one in five people with schizophrenia has this risk gene.
Researchers found that 17 of 81 individuals with schizophrenia - 21 per cent -
had inherited the uncommon Nogo variant gene from both parents. In a control
group of individuals without schizophrenia, only three per cent had inherited
the gene from both parents. People can inherit the variant Nogo gene from just
one parent but there's a schizophrenia risk only when this gene is inherited
from both parents. The gene does not suggest a diagnosis for schizophrenia but
rather an increased predisposition to the illness.
One
of the Nogo gene's functions is to produce proteins that inhibit the growth of
nerve endings in the brain. Unlike the common form of Nogo, the variant gene
has three extra chemical bases, known as CAA, in a region of the gene that
regulates protein production. The researchers found that activity of the Nogo
genes was higher in the post-mortem brain samples of individuals with
schizophrenia. It is possible that these extra CAA bases lead the variant Nogo
gene to produce more proteins, thereby reducing the number of nerve endings in
regions of the brain associated with schizophrenia symptoms, Seeman says.
However, more research is needed to confirm this.
"This
study adds to the rapidly evolving theory that, in the brain of those who
suffer from schizophrenia, the nervous system develops in a slightly altered
fashion leading to the onset of symptoms such as hallucinations and delusions
in young adulthood," says Seeman.
Although the cause of schizophrenia is not known, the treatment of the
symptoms has been well-established since the 1970s. Antipsychotic medication
is used to block the action of dopamine, an adrenaline-like chemical
transmitter in the nervous system that becomes overactive in people with
schizophrenia.
"This
finding of a risk gene in the general population could lead to the development
of medications outside the dopamine system, perhaps targeting the protein
produced by the gene," suggests Seeman.
The
study was supported by the National Alliance for Research on Schizophrenia and
Depression, the Eli Lilly Research Fellowship in Women's Mental Health, the
Stanley Foundation Scholars Mentors Program of the National Alliance for the
Mentally Ill, the Canadian Institutes for Health Research, the Ontario Mental
Health Foundation and the National Institute on Drug Abuse. Professor
Tallerico is an Essel Investigator of the National Alliance for Research on
Schizophrenia and Depression (NARSAD) and Professor Seeman is a Janice Lieber
Investigator of NARSAD.
The
University of Toronto, Canada's leading research university with 60,000
students, is celebrating its 175th anniversary in 2002.

Schizophrenia drugs linked to diabetes
Last Updated Thu, 03 Oct 2002 15:11:37
HALIFAX - Some doctors are warning about a class of anti-psychotic drugs
linked to life-threatening side effects.
Health Canada has received reports that Zyprexa is suspected as the cause of
four diabetes-related deaths. The drug was approved for use in Canada in
1996 and is made by Eli Lilly.
Zyprexa is part of a new class of drugs called atypical anti-psychotics. A
growing number of schizophrenics in the country are using the new drugs, such
as Clozaril. There are 300,000 schizophrenics in Canada.
People with schizophrenia experience three major types of symptoms:
psychotic symptoms: delusions and hallucinations
deficit symptoms: diminished emotions, social withdrawal and low motivation
mood symptoms: depression to suicidal
"It
helps me by calming me down because I'm also nervous, my legs shake and my
hands tremble," says Richard Thompson of Edmonton who has gained more than 30
pounds (14 kg) and developed diabetes since taking the drugs. His doctors
believe the drug is at least partly responsible for his weight gain.
The
most common side effects associated with Zyprexa are:
drowsiness
insomnia
agitation
dizziness
Less common effects include skin rash, depression, fast heart rate and
constipation
Other known, but less common, effects are listed as: skin rash, headache,
depression, fast heart rate, constipation and weight gain.
Research published in the British Medical Journal and other journals suggest
atypical anti-psychotics can cause diabetes.
"We
suspect…those drugs interfere with some kind of chemical processes both in
the brain and body and lead to the development of something called insulin
resistance," says Dr. Pierre Chue, Thompson's doctor. "As that develops, the
diabetes sets in."
Health Canada has received four reports of diabetes-related Zyprexa deaths
over five years.
Two
of those deaths involved teenage boys who fell into diabetic comas.
In
the U.S., the government has collected reports of 140 people who developed
diabetes after taking Clozaril.
The
companies which make the drugs say people with schizophrenia tend to have
unhealthy diets which put them at risk of getting diabetes.
Marie Josee-Poulin, a psychiatrist at Laval University in Quebec, says the
evidence linking the drugs to diabetes isn't clear yet but she says the
concerns are justified.
A
Health Canada newsletter has warned doctors that atypical anti-psychotics
may be associated with new cases of diabetes. Some doctors would like to see
this as a clear warning on the label.
Both Poulin and Chue says too many doctors are unaware of the risks and side
effects of the new class of anti-psychotics. They say patients should be
closely monitored for signs of unstable blood sugars or weight gain.
Written by CBC News Online staff
 | 
The
New York Times, September 15, 2002
When Politics Is Personal - (Senator Pete V. Domenici and the shaping of the
US Govt. policies on brain diseases/mental illness).
By
Deborah Sontag; Deborah Sontag is a staff writer for the magazine.
'My
daughter Clare, and it's spelled c-l-a-r-e, she's my fourth child of eight,"
Senator Pete V. Domenici began reluctantly, his voice soft and gravelly.
"Clare was a beautiful, beautiful girl. Now she's all grown up, and she's,
well, she's struggling. Struggle is a good word for it."
Domenici had been sitting beside me in an armchair in his Washington office,
chatting about a re-election race that is causing him little anxiety. But
when the conversation shifted to his family, and then specifically to his
40-year-old daughter, Clare, he rose abruptly and moved away, putting his
solid senatorial desk between us. Sitting beneath a Navajo wall-hanging from
his native New Mexico, he absorbed himself lining up pens on a yellow legal
pad. A 70-year-old Republican, Domenici is not a soul-bearing, confessional
type, and he has zealously guarded his family's privacy during his nearly
three decades in the Senate. "Personal stuff," as he calls it, makes him
squeamish; he'd rather talk about taxes or nuclear energy or almost any
piece of pending legislation. With what looked like a nod to himself,
however, he continued. "Clare was a very marvelous gifted athlete," he said.
"In her best year in high school, she was district champion in tennis; she
was a catcher on the baseball team; she was an absolutely outstanding guard
on the basketball team." During her freshman year at Wake Forest in North
Carolina, however, Clare started to lose her zest, growing "fuzzy" and
inordinately indecisive. She would call home frequently for guidance on
simple issues, "like what kind of potato to have," Domenici said. "She was
all out of whack. Then my wife, Nancy, went down there to help her and ended
up bringing Clare back home. That's when things got really out of hand. Her
temperament totally changed. She became angry, mean. Throwing things at
mirrors. Cussing, swearing. Crying, shrinking into a shell, taking to her
bed. And that started two novice parents down the strange path of having to
believe something we didn't want to believe. And to really believe it, to
acknowledge that Clare was mentally ill, took a long time."
As
Domenici exhaled, his assistant tiptoed in to give him a note, and he asked
her hopefully, "Meredith, do I have to go to an appropriation meeting?" The
assistant shook her head, but Domenici had revealed all he wanted to about
Clare for the moment. So he switched gears and talked, in his distinctively
folksy and rambling way, about how the happenstance of Clare's illness had
redirected his political agenda. If it were not for Clare's struggle with
what was finally diagnosed as atypical schizophrenia, it is improbable that
Pete Domenici, Mr. Fiscal, would have assumed the unlikely role of champion
for the mentally ill. "I don't believe the subject ever would have come up,"
he acknowledged.
Domenici had made a name for himself as the Republican Party's budget
expert. He was a gray, pragmatic fiscal and social conservative who opposed
abortion, gun control and same-sex marriage and supported school vouchers,
tax cuts and mandatory three-strikes sentencing. He was no bleeding heart,
no cause-pleader. But Clare's troubles led Pete and Nancy Domenici into
what, 18 years ago, seemed almost like a secret world inhabited by all those
whose lives had been touched and ineluctably changed by mental illness. "And
once I got into it, I wouldn't have gotten out of it even if somehow Clare
would have come out of my mind," Domenici said. "You get into the world of
these dread diseases -- you hear stories -- they're terrible from the
standpoint of what's happening to these people and what's happening to their
families. Society was just ignoring them, denying them resources."
It
is strange to think that government works that way, that the fact that a
senior senator has a mentally ill daughter can spur governmental action on
mental illness. Yet on many issues, politics really is that personal and
lawmaking that arbitrary. "You'd be surprised how often legislation is
directly informed by our lives," Lynn N. Rivers, a Democratic member of the
House from Michigan, says. "In the field of mental health, I think it's
possible that nothing at all would have been done by Congress if it weren't
for legislators like Domenici who were galvanized by personal experience."
Rivers herself has had very direct personal experience; she is a
manic-depressive. At a committee hearing this spring, after a couple of
witnesses suggested that mental illnesses were not really illnesses, she
snapped open her purse and extracted an amber vial -- the pills that keep
her healthy -- and shook it like a maraca as if to wake them up.
Over a decade ago, when Domenici embraced the issue, mental illness was not
on the national agenda. Americans didn't like to think about it. Even now,
although the subject has come out of the shadows and Prozac is in many an
American medicine cabinet, Americans remain skeptical and judgmental.
Domenici knew that he was growing impassioned about an issue that many of
his colleagues would consider marginal, even distasteful, and that he needed
colleagues who had been shaken personally, too. He ended up joining forces
with a quite liberal Democratic senator, Paul Wellstone, whose older brother
had grappled with severe mental illness for many years. Together the "odd
couple," in Wellstone's words, nurtured bipartisan alliances with former
Senator Alan Simpson, whose niece committed suicide, and Senator Harry Reid,
whose father killed himself, and Tipper Gore, who has suffered depression,
and Representative Marge Roukema, whose husband is a psychiatrist, and
Representative Patrick Kennedy, who has also battled depression, and Senator
Edward Kennedy, Patrick's influential father, and Rivers. "There has been a
personal, crystallizing experience in each of our lives," Wellstone says.
"You almost wish it didn't have to work that way, that all of us would care
deeply anyway about people who were vulnerable and not getting the care they
need. But this kind of thing happens a lot in politics for fully human
reasons."
For
10 long years, Domenici and Wellstone have focused their energies on a law
that would force health insurers to treat mental and physical illnesses with
full parity. They consider it civil rights legislation, but insurers and
employers -- potent lobby groups who view it as a costly and unnecessary new
mandate -- have largely succeeded in blocking it. Suddenly this year,
however, the two senators feel tantalizingly close to achieving what once
seemed a nearly impossible goal. It is odd timing, given the political
preoccupation with terrorism, corporate misconduct and Iraq. But perhaps,
after "A Beautiful Mind" won its Academy Awards, this was destined to be the
year when the mentally ill received their due. Or perhaps it is simply
because Pete Domenici has a friend in the White House, and his friend owed
him one, and that's the way the chit system known as government works.
When we talked in his office, I asked Domenici if he kept a picture of Clare
in the extensive gallery of family photos behind his desk. "Sure," he said.
Then he peered over the top of his glasses and rooted around. "Hmmm," he
said. "Well. Hmmm. Well. I guess I don't have her here, and I'll have to fix
that." He handed me a faded family portrait that looked to be from the
1970's. "That's her right there," he said, pointing to a wan girl with a
faraway gaze. "I guess she has a little sad look in that one, doesn't she?"
He then ambled over to a display wall adorned with professional artwork from
New Mexico. In one corner hung two childlike watercolors -- a vase of
flowers and a cluster of sea gulls signed "To Dad, From: Clare." A flicker
of a smile crossed Domenici's face. "She's not half bad," the senator said.
The
Domenicis live in Washington, down the street from the Ashcrofts and a few
blocks from the Senate in a house identifiable by the red chili peppers --
New Mexico's state vegetable -- dangling beside their front door. Clare
lives by herself in an apartment in Albuquerque, with two siblings, four
aunts, a boyfriend, a case manager, a job coach, a counselor and a doctor on
hand to help her cope. Clare does not have hallucinations or delusions,
which is why her schizophrenia is labeled atypical. Atypical schizophrenics
suffer from losses -- of will and drive, of the ability to experience joy
and pleasure, of cognitive functioning. Their affect tends to be flat and
their thinking irrational at times.
In
Clare's case, this produces debilitating anxiety. Clare's younger sister
Paula Domenici, who is a psychologist, described Clare's daily life as
racked by "anguish and hell." Nonetheless, like many atypical schizophrenics
who respond well to the new low-dose antipsychotic drugs, Clare has found a
treatment regime that allows her to be quite functional when she sticks to
it. She works; she drives; she sings in her church choir; she plays tennis
at an Albuquerque tennis club -- and wins," Paula says. But Clare's
condition fluctuates. Recently, she took a leave from her job sorting mail
because the stresses of the mail room were getting to her. "Any little thing
can rock the boat," Paula says. "She gets very hurt very easily."
The
Domenicis have grappled for years with how to balance their daughter's right
to, and need for, privacy against the potential public good of talking
openly about a senator's daughter's mental illness. "We would ask ourselves,
'Will it do her harm or not?"' Domenici said. And until now, they have
always erred on the side of playing it safe, since they are not people who
like to talk about themselves anyway. In our first conversation, Domenici
squirmed, his eye on his watch. Subsequently, though, he made the decision
to surmount his discomfort because he thought it might serve his political
ends. Besides, it was his wife who was the really private one.
When I first called Nancy Domenici, who is considered a lay expert on mental
health by many in the field, she said: "Gosh, why me? I'm not the most hep
person on the subject of mental illness." Eventually, her husband persuaded
her to talk. "I didn't want to end up divorced," she joked. Still, because
she is either protective or overprotective, she body-blocked the idea of my
talking directly to Clare. She said that Clare was simply too "wobbly" right
now.
We
chatted at her kitchen counter, sipping tea from mugs with rose handles
beneath a clock that chirps a different birdsong on every hour. At one
point, after the finch cried noon, the phone rang, and Nancy Domenici let
the answering machine pick up. "Hi, Mom, this is Clare." Clare was calling
in to report to her mother that she would be going to the doctor at 2 p.m.
and to her "weigh-in" at 4. (One side effect of her medication has been a
weight gain that makes Clare look matronly, and it bothers her, her parents
said.) Clare's voice sounded thick around the edges, and it lingered
afterward in the air between us.
In
a senate coffee shop, with a cup of Starbucks by his side, Domenici doodled
on his daily press clippings. "Me/Bush," he wrote. He told me he had always
hoped that the stars would line up as they now have, with a president in
office whom Pete Domenici had helped elect. "Here's how it worked," Domenici
said. "He's kind of my friend. He gets elected. I know there's one thing I
really want to do above most other things. I wait a few months after he gets
in, and then I request a meeting."
In
1996, Domenici and Wellstone enjoyed their first success after four years of
trying to overcome Congress's reluctance to address the problem of
inequitable and inadequate insurance coverage for mentally ill Americans.
Making a lot of compromises, they won approval for what Domenici now calls
"mental illness coverage lite," a first step. The Clinton White House
helped, and especially Tipper Gore, who a few years later would disclose her
own experience with depression. Newt Gingrich, then the Republican speaker
of the House, didn't actively assist but, after a visit from Domenici, he
didn't block the legislation either -- which mental-health advocates
attribute partly to the fact that Gingrich's mother suffers from bipolar
disorder.
Still, the Mental Health Parity Act of 1996 was limited in nature and in
effect. It mandated equal annual and lifetime dollar limits for mental and
physical benefits; lifetime limits for mental-illness coverage used to be
capped at about $125,000, compared with about $1 million -- or sometimes no
limit -- for physical disorders. But it allowed employers to comply with the
letter rather than the spirit of the law, shifting their costs by raising
co-payments and deductibles or lowering limits on hospital days and
outpatient visits.
Many states, meanwhile, introduced mental-health parity laws that go further
than the federal government's. But even those states possess limited ability
to regulate self-financed employer health plans, so Domenici and Wellstone
wanted a broad piece of federal legislation that would set the standard.
With the 1996 law due to expire by year's end anyway, they are pushing to
create the first comprehensive mental-health equitable treatment act.
Mental-health advocates say it will make things infinitely fairer. Without
parity, the middle-class parents of a newly psychotic 19-year-old son, say,
might discover they have a 30-day lifetime limit on psychiatric
hospitalization; that limit might be reached before his illness is even
diagnosed, much less treated. They would be left then with three options: go
into debt, forgo treatment or turn to the overburdened public sector. If
their son had been in a serious car accident, they would face no such
predicament.
The
Domenici-Wellstone law does make some allowances for the business
community's concerns. It does not mandate coverage of mental illnesses; it
mandates equal treatment of physical and mental illnesses where such
coverage exists. It exempts businesses with less than 50 employees. It
doesn't include substance abuse. But insurers and employers are tired of
Congress's interference, and they do not see this as a civil rights issue.
"There is no right to health care," says E. Neil Trautwein, director of
employment policy for the National Association of Manufacturers. "If this
issue gets cast that way, it's unfair, and it kind of makes us look like the
bad guys. Our members are already providing voluntary coverage."
Many insurers and employers maintain that the parity legislation is
misguided, that it will end up backfiring and prompting some providers to
drop mental-health coverage entirely. They say that parity for
mental-illness coverage, as designed, will drive up health-care costs and
that the legislation defines mental disorders so broadly that people with
problems like caffeine intoxication or jet lag will abuse the system.
Recently, however, these opponents have lost ground. While Domenici had a
couple dozen co-sponsors in 1992, when he first introduced mental-health
legislation, he now has 66 senators with him on this. He has been
unsuccessful, however, in reaching across the Hill and persuading the House
leadership to join him, even though a majority of House members are on
record as supportive. And that's why Domenici paid his visit to the Oval
Office in July of last year.
Domenici was pleasantly surprised that Bush took the issue seriously enough
to ask Andrew Card, his chief of staff, to attend. The senator wasn't
certain whether he needed to start at the beginning, to explain that
diseases of the brain are as real as diseases of other organs and that they
are treatable. "I just plain didn't know where he was on the mental issue,"
Domenici said. "But I was only a few sentences into it before he stopped me
and said, 'On the issue of is this a disease, I've already gone up that
mountain."'
Dr.
Samuel Keith, chairman of the psychiatry department at the University of New
Mexico, participated in a round-table discussion on mental health with Bush
in the spring. The president said that he had grown up thinking people with
mental problems should just read the Bible and try harder, Keith said. But
then, according to Keith, the president told the round-table participants
that a close friend in Texas who was profoundly depressed went off and got
treatment and returned a transformed man. This opened his eyes, the
president said.
The
president was also sensitized by the suicide last year of Heinz Prechter, a
Michigan businessman, Domenici said, although he was not sure whether Bush
had told him this or someone else had. Prechter, who made his fortune after
introducing the sunroof in the United States and was a generous donor to the
Republican Party, killed himself at the end of a lifelong struggle with
bipolar disorder.
During that meeting at the White House last year, Bush told Domenici that
2002 would be a better year. In late April of this year, as promised, Bush
flew to New Mexico to stand beside Pete and Nancy Domenici, endorse "full
mental health parity" and pledge to get federal legislation passed by year's
end. Since then, Bush hasn't put real muscle behind his pledge, and his
priorities are clearly elsewhere. Domenici, though, takes it on faith -- a
seasoned politician's faith -- that the president will make good on his
promise. And the mere fact of Domenici's securing the president's
endorsement has forced the law's longtime opponents to think about
compromises.
"Our vast preference is no additional mandates, but we don't want to be in
an antagonistic position with a longtime friend like Senator Domenici," says
Trautwein of the manufacturers' group. He suggested that the manufacturers
would consider a narrower version of the law that mandated parity for
serious brain-based illnesses like schizophrenia rather than all mental
disorders. "We heard the president, and we can count noses. We don't want to
see this issue rewound and replayed in the next Congress."
When the Domenicis told Clare that she was going to be part of a magazine
article, she didn't have much to say in response. It has always been
difficult for Clare to see her situation clearly, her sister Paula says:
"Sometimes now she'll say she has a mental illness, which is good. Ten years
ago, she wasn't coherent enough in her thinking to realize she was ill."
Ten
years ago was a low point. Clare, who was then still living in Washington,
would find herself driving around in a fog, unsure of what she was doing or
where she was. Eventually, she checked herself into a psychiatric hospital.
It was the first and last time that she was hospitalized, her mother says,
locked in a closed unit with other mentally ill people, some withdrawn like
her and others quite manic or psychotic. During that time, though, Clare was
retested, and the Domenicis ended up with a clearer understanding of the
chronic nature of her illness and with a better course of medications.
It
had been obvious since Clare dropped out of college that her functioning was
abnormal, but her family initially thought she was in some kind of extended
funk. Maybe it was allergies; it couldn't have been that baseball that
struck her in the neck, could it? They didn't know where to turn. "We were
kind of in the dark ages in terms of being willing to see a specialist," the
senator told me.
Eventually, they found their way to specialists and more specialists. But
Clare's symptoms were not clear-cut, making it hard for doctors to diagnose
her condition and thus for some in her family to accept that she was in the
grip of something that she couldn't snap out of. At a certain point, the
senator said, so many years had gone by that "you gotta acknowledge the
behavior is not normal and it's probably going to be there for a while."
That acknowledgment, he said, was scary. "When you finally arrive at the
conclusion that your child has schizophrenia, you have thoughts of suicide,"
he said. "They threaten. You really don't know if they're going to follow
through. In our case, nothing has happened. But we know friends where
something has, and there probably isn't a hell of a lot of difference
between the one who does it and the one who doesn't."
Some time after Clare's hospitalization, she moved back to New Mexico. Her
family thought that it would be a good idea to get her out of urban D.C. and
at something of a distance from her mother, on whom she was extremely
dependent. Clare lived for a while in a group home near a state farm in
Carlsbad, where she worked as an assistant sports counselor for the mentally
retarded residents of the farm.
For
a time, Clare was covered by Medicare, since she was collecting Social
Security disability insurance payments. Medicare's coverage for mental
health is quite skimpy -- only half of treatment costs and no prescription
drugs unless you're hospitalized. When Clare started working, she was
covered by her employer; the H.M.O. authorizes a limited number of
psychiatric visits a year, but Clare's doctor, on her mother's prodding,
keeps reauthorizing visits. Nancy Domenici juggles the volumes of paperwork,
keeps on top of the bureaucracy and pays out of her pocket for all costs
that are not covered. "What if Clare had no parents?" she asks.
Years ago, a neighbor of the Domenicis told them about the National Alliance
for the Mentally Ill. The senator and his wife went to a meeting in a church
basement and discovered a world of parents dealing with the same issues
facing them. "It was a godsend," Nancy Domenici says. And for the alliance
too. Pete Domenici heard a lot of depressing stories with bad endings:
families going broke, splitting up; mentally ill children ending up on the
streets, in jail or dead. Bit by bit, the advocates lured Domenici into
involvement, a speech at a convention here, an appropriation there.
It
became clear to Domenici that he could do little about one of the most
pressing needs, which is an overhaul of the public mental-health system,
since that is largely the responsibility of state and local governments. So
he focused on what he could get done. He pushed successfully for increased
federal appropriations for research into brain diseases, threw his weight
behind a private research foundation and backed programs that dealt with
housing, public education and the mentally ill who are homeless. Every once
in a while, he told me, someone would say to him, "Isn't it good for severe
mental illnesses that your daughter got one of them?" He found that
distasteful.
Domenici never expected such a protracted battle on the parity legislation,
and he is tiring of it. Wellstone is downright antsy, anxious about the
president's follow-through. "I haven't seen the evidence yet that the White
House will deliver," he said. "I'm certainly more impatient than Pete." But
then they are kind of different. Wellstone once called Domenici's office,
and an assistant asked him the subject of his call. "I answered: 'Mental
health! What the hell else do we agree on?"' Wellstone said.
Unlike Domenici, Wellstone speaks with the cogent passion of a defender of
the vulnerable and neglected. He fits more closely the image one might have
of a lead advocate for this cause. He traces his political awakening itself
to a visit he paid as a 10-year-old to a state mental institution where his
college-age brother had been hospitalized after a breakdown. Wellstone's
parents had gone deep into debt trying to sustain his brother in a private
clinic once their insurance ran out, and the public hospital was a snake
pit, he says. "My energy on this issue is fired by tremendous indignation,"
Wellstone says.
Rivers, similarly, is a natural heroine for the cause. She graduated from
high school pregnant, married her high-school sweetheart and started her
adult life as a mother bedridden by severe depression. It took her almost a
decade after her illness was diagnosed as manic depression to find a mix of
medications that would allow her to be symptom-free. Eventually, though, she
earned a law degree, became active in local politics and was elected to
Congress in 1994 despite acknowledging her illness. ("You betcha!" she said
when a caller to a radio show, obviously a plant, asked if she had ever been
depressed. "And so have millions of other Americans!") At times, she and her
former husband, a boiler engineer, were spending half their take-home pay on
her barely insured treatment, so she takes the parity issue very personally.
The only possible explanation for employers' and insurers' reluctance to
cover mental illnesses on a par with physical illnesses, she says, is
"ignorance or greed."
Last year, when Rivers learned that she would have to face Representative
John Dingell in a Democratic primary after her district was redrawn, she was
beset by anxiety. But not for political reasons. "The one thing that
frightened me was not running against the dean of the House, not all the
money he was going to have, but this terrible fear that if I lost, I would
lose my health insurance." Rivers is covered under a federal employees' plan
that guarantees full parity coverage. "I am not smug enough to believe that
I am not at risk of relapse, and my terror is getting sick again without
having appropriate insurance," she said in July. Dingell did indeed beat
Rivers in the August primary, leaving her to face these concerns.
In
contrast to Wellstone and Rivers, Domenici can seem uninspired, even
inarticulate, in making his case. He uses euphemisms, talking about mentally
ill people as being "under the shell" or "coming out from the shell" after
treatment. He asks: "Is a severe schizophrenic 19-year-old who's been
catatonic -- they finally got him out of it but now he's gained weight and
weighs 300 pounds because that's the side effect -- is that less bad than
someone with cancer?" But advocates for the mentally ill believe that
Domenici's folksy awkwardness on the subject of mental illness can be quite
effective, precisely because the subject makes many Americans uncomfortable.
And it is, they suggest, also something of an act. Domenici's expertise is
probably unparalleled on the Hill, they say, and more important, it is his
political know-how, the way he bargains behind closed doors, that counts.
Andrew Sperling, legislative director for the National Alliance for the
Mentally Ill, says that Domenici has played a singular role precisely
because he is such an unlikely advocate. "If the parity legislation had come
along as a Kennedy-Wellstone initiative, it would never have been taken
seriously in the Senate. Democrats come up with mandates on health insurance
every day. But when a senior Republican senator with a fairly conservative
voting record comes forward and says that in this instance the federal
government has a responsibility to set a standard on the marketplace -- it
has the flavor of a Nixon in China."
As
year's end approaches, Domenici knows that Clare's law, like Clare herself,
needs to be watched and tended if it is not to be overlooked or derailed. He
hesitantly confided that he expected Clare to marry in the near future, and
it is clear that he is ready for some kind of ceremony -- the Rose Garden,
maybe -- on the legislative front too. "We've been doing this for a long
time," he said, "and I am older than some people think."
|
 | 
|
 |
California, US - LAURA'S LAW SIGNED BY GOVERNOR DAVIS
NEW LAW REFORMS TREATMENT OF SERIOUSLY MENTALLY ILL
GOVERNOR DAVIS SIGNS LAURA'S LAW 9/28/2002
'Laura's Law' Will Allow Court-Ordered Treatment Of Mentally Ill.
By
Dan Morain And Carl Ingram, Times Staff Writers
SACRAMENTO -- Gov. Gray Davis signed legislation Saturday permitting
authorities to treat severely mentally ill people against their will if
judges conclude that they cannot care for themselves and are likely to
become dangerous.
The
legislation represents a significant amendment to a state law that
protects the civil rights of mentally ill people, the 30-year-old
Lanterman-Petris-Short Act. The act helped lead to the emptying of
state hospitals, which once housed more than 30,000 people but now care for
4,000. All but about 800 of those remaining patients have committed
crimes and were sent to institutions by courts.
The
legislation, Assembly Bill 1421, establishes a hearing process in
which judges will determine whether the person has a history of failing
to comply with treatment and has, within four years, exhibited "serious
violent" behavior against others, or tried to hurt himself or herself.
The individual could be represented by a public defender or a private
lawyer.
Davis said he expects the measure to help reduce homelessness,
hospitalization and involvement in the criminal justice system.
"This is a critical step in helping the seriously mentally ill, as well
as their families," Davis said in a statement, predicting that the bill
would "help end the cycle of hospitalization, quitting treatment and
relapse."
Davis' decision to sign the bill marked a victory for Assemblywoman
Helen Thomson (D-Davis) in her final year in the lower house. Thomson
tried for five years to win approval of the measure, which was backed
by law enforcement and many family members of the mentally ill. Liberals
in the Legislature, siding with some patients' rights activists, had
blocked its passage until this year.
Thomson called the final version of the bill "Laura's law," named for
Laura Wilcox, a 19-year-old woman who worked at a Nevada County mental
health facility and was killed by a man whose mental illness had gone
untreated. It is similar to a New York law adopted in 1999 after a
mentally ill man pushed 32-year-old Kendra Webdale into the path of a
subway train.
As
part of the compromise, counties will have the option of
participating, and would bear the costs. People would be treated in
expanded outpatient programs considered the "least restrictive"
necessary to achieve recovery.
Under current law, people generally can be detained for 72 hours. In
extreme cases, they can be held for six months. The law provides
parents and other family members of adults who are mentally ill little or no
opportunity to intervene on the individual's behalf. Thomson's bill
will allow family members to testify at hearings.
"I
don't think it will have any impact on the population in state
hospitals," said Stephen W. Mayberg, director of the state Department
of Mental Health. "Our goal is to treat people not in institutional
settings."

Marketletter, September 2, 2002
UK law and upcoming injectable drugs to treat schizophrenia and bipolar
disorder
Manufacturers of antipsychotic drugs are set to launch longer-lasting
injectable products which will help combat the problem of poor patient
compliance in the treatment of schizophrenia and bipolar disorder, says new
research from Datamonitor.
These drugs, which include Novartis' Zomaril (iloperidone) and Bristol-Myers
Squibb's Abilitat (aripiprazole), may have an important role if the UK
government's bill to force treatment of community patents is passed, because
they can ensure that the drugs are taken once every two weeks or possibly
monthly, it adds.
However, the study warns that antipsychotic injections are likely to have
mixed success. While they are particularly useful when treating patients in
the acute phase of schizophrenia, the length of efficacy may be subject to
controversy, as administering long-lasting medication decreases the ability
of the patient to influence their own treatment, which is considered a
patient right in most circumstances. In June 2002, the UK government
proposed several changes in the treatment of the mentally ill, one of which
will force patients in the community to undergo treatment without the need
to be sectioned. In this situation, a long-acting antipsychotic would be
particularly useful, says Datamonitor, because patients in the community
could visit a health care professional every two weeks, or possibly every
month, and compliance could be ensured.
A
major issue in treating patients who suffer from spells of psychosis is
that, once their health improves, they are allowed into the community.
However, their chances of staying healthy are reduced because they are not
obliged to continue taking medication, says the report, which adds that the
introduction of longer-lasting drugs should increase patient compliance
greatly and, as such, help to reduce this risk.
Nevertheless, Datamonitor believes the future treatment of these disorders
will reside in receptor-specific compounds that can be combined into a
tailor-made polytherapy to suit an individual's needs, with movement towards
this type of therapy already being seen in early-stage programs.

|
 | New
Book: "Beyond Crazy" by Julia Nunes and Scott
Simmie, published by McClelland & Stewart. Sept 2002
ISBN 0-7710-8068-9 $34.99 Canadian dollars
********************************************
Toronto Star October 1, 2002
No
looking back
By
Julia Nunes and Scott Simmie
With
the help of her mom, an indomitable young woman tames a terror from the past
|
 | This
is a tale of two generations. It's a sad story that leads to a much happier
one. And it begins in 1980, in the small Northern Ontario city of Sault Ste.
Marie. Terry-Lee Marttinen is 16 years old, dating a young man named John (a
pseudonym) when she discovers she's pregnant. Something equally unexpected is
happening to John. His behaviour has become increasingly bizarre: he's smoking
marijuana, dabbling in the occult. Terry-Lee is scared; she stops seeing him.
Over the next four years, John winds up in and out of hospital. Much later -
too late - doctors determine he's been suffering from schizophrenia.
One summer day in 1984, when his daughter Tara is 3, John succeeds after
several attempts at suicide. He is 22 years old.
About a decade later, another young life is entering those delicate teen
years. And Tara Marttinen is herself beginning to feel different. To the
outside world, nothing is seriously wrong. After all, what teenager doesn't
stay up late or let their grades slip slightly?
Then one day as she sits at her desk in class, he hears, for the first time
ever, a voice in her head. "It was out of the blue. I heard: 'Take off your
shoes and sit under your chair.' Really loud, sort of screaming in my ear."
For the next several months she carries on with her classes, her meals with
her mom, and nights out with friends as if nothing's wrong. She shares her
secret with no one. But late at night, she lies awake for hours, lost in a
jumble of racing thoughts.
At 16, partway through Grade 11, Tara finally "spills the beans" to her
mother. And immediately, Terry-Lee thinks of schizophrenia. "When she told me
she was hearing voices, I knew instantly. Just instantly. My little back went
up and I was instantly fearful."
We meet Terry-Lee and Tara at a cafe in downtown Toronto. It's the start of a
mini-vacation they've been planning for weeks. Together, they're visiting
relatives, taking in the sights, and "shopping, shopping, shopping."
Mother and daughter have matching blond hair, blue-grey eyes, and friendly
smiles. When one speaks, the other nods; often, they finish each other's
sentences.
"We've been together a long time," Terry-Lee says proudly. "Just me and her.
Being a young single mom, I think Tara and I have been really close."
Tara nods in agreement. "I actually like hanging out with my mom. ... It's
relaxing to be around someone who understands you." Tara is wafer-thin with
finely carved cheekbones, alabaster skin, and a small silver hoop through her
left eyebrow just above her funky black eyeglasses.
"We're very lucky," she says. "I'm very lucky."
Tara and Terry-Lee want to share the story of what's made them lucky. Of how
they got from there to here. There was Tara sitting alone in her room, writing
page after page of anguished poetry. Here is Tara finishing high school with
honours, Terry-Lee preparing to send her off to university. "I'm relieved,"
Terry-Lee says. "I was so scared. And now I know it's okay. I have a safe
feeling inside."
The one thing Terry-Lee knew when she found out about the voices was that Tara
needed help away from home. "I just made the assumption that the care wouldn't
be any good in the Soo because of Tara's father's care."
With a phone call to a distant uncle who worked in the mental health field,
Terry-Lee arranged an appointment at a clinic in London, Ont., seven hours
away by bus. They didn't know it at the time, but what they'd stumbled into
was a leading-edge treatment facility for first-episode psychosis. Dr. Ashok
Malla runs the Prevention and Early Intervention Program for Psychoses, or
PEPP. Soon they were sitting in his office as he led them through a clinical
assessment.
Straight away, Dr. Malla recognized the early signs of psychosis. Before he'd
even diagnosed Tara with schizophrenia, he prescribed a low dose of an
atypical antipsychotic medication. "If we see symptoms, if they've been there
for more than a week, we treat them," Dr. Malla says.
Tara was also given a brain scan in a magnetic resonance imaging machine.
"That was the scariest thing," she says. "But I just had this feeling: After
this it's going to be better."
Tara was never hospitalized, never needed to be. Instead, she and Terry-Lee
returned home and went on with their lives.
Slowly, the voices faded away. But other challenges remained. Schoolwork was
harder than it had been, and even hanging out with friends could be
exhausting. "I missed, on average, one day a week out of school. ... I'd be
wiped out. There was too much going on."
Tara was tackling head-on the kind of life changes none of her friends were
interested in making. Late-night partying gave way to quieter activities:
jewellery-making, journal-writing, embroidery. The junk food was tossed - no
more Cheez Whiz sandwiches - and replaced with a high-protein, low-sugar diet
bolstered with vitamins. (Terry-Lee had done the research on
the Internet.)
Twice a year, mother and daughter made the long trip to London for
consultations with Dr. Malla.
If all this sounds simple, it hasn't been, as Tara wrote in a PEPP newsletter:
"I can't for even one day (diverge) from my regimen of taking my vitamins,
going through my day free of over-stimulation, then taking my medication, and
finally, going to bed at a decent hour. If one of these elements were missing
it would have drastic effects on my performance the next day."
The payoff, however, has been huge. In five years, Tara has never had a
relapse. "I know when something's wrong," she says, "and when I should rest."
Dr. Malla is thrilled with Tara's progress. "She has a vision of her life," he
says, "of what she wants to do."
What Tara wanted to do, after high school, was go to university. In Sault Ste.
Marie, that meant leaving home. "We're trying to be realistic," Terry-Lee
says. "Do the homework, cover the bases, and then leap off the cliff."
The homework included choosing university in London, where Dr. Malla is. Tara
worked for a year after high school to save money. She applied for student
loans, and won scholarships to help pay for tuition and books. And she decided
against a room in residence - "too chaotic, too much going on," says Tara.
Today, the results of all that can be found on a secluded street in a clean
and cozy apartment in an old house. This is Tara's new home, the start of her
new life. "I like living on my own right now," she says. "It's very
comfortable. It's my own space."
Tara is pacing herself carefully. Taking three classes (English literature,
calculus, psychology) instead of a full course load of five. Keeping the usual
first-year socializing to a minimum. "I'm a loner anyway," she says with a
self-deprecating laugh.
In her mind's eye, she carries a picture of the future. A four-year honours
degree in psychology completed over five years, including summer classes and a
full course load in the final year. After that, a career counselling teens
with mental health issues. Even further down the road, she foresees marriage
and kids, and perhaps a chance to be medication-free. "If for some reason my
brain's sort-of levelled out again ... I don't want to be on meds and having
kids."
But for now, she's focused on school. She says she's not even looking for a
boyfriend. "I don't want to be with a person who doesn't respect my illness
and understand the importance of it," she says firmly. "It's a big part of my
life. I don't want it to be, but it is. It's something I have to deal
with, and they would, too, as a result of being with me. ... And I don't think
right now anybody's prepared for that."
Back at the cafe table, Terry-Lee shakes her head, amazed. "She's wise. She
freaks me out. But I understand why she's wise. Tara's spent more time
thinking about the meaning of life than most people do in a lifetime."
Tara, slightly embarrassed, allows that she has "grown up fast." But she
finishes her thought in a way that reminds us she isn't too grown-up just yet.
"It's like you're sixteen," she says, "and suddenly feel thirty, you know?"
Because the comment draws laughter from the rest of us at the table, Tara -
ever considerate - adds: "Forty, eighty, whatever. More like eighty." Then,
discreetly, she smiles.
Tara
Marttinen is now in her second year of university. This is a condensed excerpt
from the book "Beyond Crazy"
by Julia Nunes and Scott Simmie,
McClelland & Stewart. ISBN 0-7710-8068-9
http://www.mcclelland.com/catalog/display.pperl?isbn=0771080689 |
 | |
 | 
|
 |
Windsor Star
October 10, 2002
Path of doom starts with homelessness; Squalor 'breaks your heart'
Windsor Star
BYLINE: Veronique Mandal Star Health-Science Reporter
Angela adjusts the grocery bag on her arm, unlocks the door to her
schizophrenic son's bachelor apartment and enters a rat-infested hole. She
cries. "We've complained to the landlord a hundred times but nothing gets
done. It breaks our hearts and we want to take him home but he wants to make
it on his own," says Angela, a Windsor mom. "He's not good at standing up for
himself and his paranoia works against him because the landlord sees it and
treats him like a dog. It's almost impossible for people like him to get a
decent place to live that they can afford."
Angela's story is repeated thousands of times across Canada, illustrating the
plight of the 25 to 60 per cent of the homeless who have a serious mental
illness.
Their
homelessness sets up a vicious cycle of psychotic events leading to
hospitalization or incarceration, discharge to the streets and relapse.
"Without a proper home where they're stable, without someone to keep an eye on
them and an opportunity to have self-worth, they're lost," said Wendy Forrest,
a mental health court case manager in Toronto. "There are times when I visit a
client and walk away in tears. It breaks your heart to see where many of them
end up."
Canada's largest city has 62,000 on its subsidized housing waiting list, many
of whom are mentally ill.
"There aren't even enough of the rat holes around let alone something that's
fit for human habitation and the people most often stuck on the streets are
the most seriously mentally ill," Forrest said.
The
mentally ill, especially those with paranoid schizophrenia, often prefer the
streets to sleeping in a room with a dozen other people and consider the
street safer, she said.
In
Windsor, where up to 50 mentally ill people per night are looking for a bed,
Laura Bedard of the Schizophrenia Society of Ontario said many clients live in
rest homes. They range from excellent to disgusting. About 11 private lodging
homes house close to 400 residents.
"Some
have bathrooms with no doors, some have co-ed bathrooms, substandard food and
sleep two to six in a room," said Bedard. "We hear awful stories from people."
A
major problem for the mentally ill is the way the government pays their
disability pensions. If they are in a hospital or in jail waiting for a
psychiatric assessment longer than 30 days, their pensions are cut off and
they lose their room or apartment. They come out of hospital or jail and are
forced back on the street. |
 | 
Research yields better meds; Reducing side-effects, psychotic episodes the
goal
Windsor Star
BYLINE: Veronique Mandal Star Health-Science Reporter
Scientists attempting to design brain-shielding drugs for the mentally ill are
inching closer to curing schizophrenia.
"It
could be tomorrow but it could also be 20 years from now," said Dr. Barry
Jones, a researcher with the pharmacutical firm Eli Lilly in Toronto.
Understanding the path to a cure begins with understanding how drugs work on
the schizophrenic brain. Anti-psychotics block the overproduction of the
chemical dopamine, particularly in the limbic system, an old part of the brain
which causes psychotic symptoms -- voices and paranoid delusions. Newer drugs
also treat more emotional symptoms such as withdrawal and cognitive
dysfunction. And they reduce the debilitating motor side-effects which can
produce Parkinson-like symptoms such as the shakes.
The
drugs also block another receptor for a chemical called seratonin which makes
the frontal cortex of the brain more active. In schizophrenia the frontal
cortex is slow and affects emotion and cognitive functioning.
The
frontal cortex is the most highly developed part of the brain. It develops
last and is not complete until the mid-20s, when schizophrenia typically
develops.
"This
is why schizophrenia could develop in younger children but is not evident
until the late teens," said Jones. "It gives us our humanity, abstract
thought, motivation and decision-making. It's silent but dramatic. Psychosis
is the noisy part."
Because repeated psychotic events destroy grey matter, Jones said it's
important to develop new drugs to prevent it. A chemical in Lilly's drug
olanzapine appears to do that in a small way.
"The
aim is a brand new drug to protect the brain from psychosis," he said
Once
the genetics of schizophrenia are better understood, Jones expects the next
stage to be a cure.
Traditionally, doctors have had difficulty keeping schizophrenics on their
meds. Anti-psychotic drugs cause everything from drooling and lethargy to
gross weight gain and possible links to heart disease and diabetes.
Many
schizophrenics get fed up having to take a dozen or more pills a day.
McGill University psychiatrist Dr. Howard Margolese, a leading researcher in
the field, said while it's preferable to have patients on fewer medications,
it often takes several to deal with the symptoms.
"All
anti-psychotics are effective against the positive symptoms of schizophrenia
but we have to use an anti-depressant if the person is depressed and
anti-anxiety medication if they're agitated and sometimes they need a drug to
counteract the side-effects," said Margolese.
A
study in the British Medical Journal said the average annual cost of keeping a
person on anti-psychotics in Canada is $4,500. The average cost to hospitalize
that person is $39,000. |
|